Comparative Pharmacology
Head-to-head clinical analysis: ERYTHROCIN STEARATE versus WYAMYCIN S.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYTHROCIN STEARATE versus WYAMYCIN S.
ERYTHROCIN STEARATE vs WYAMYCIN S
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking the translocation step. It may also act as a motilin receptor agonist, stimulating gastrointestinal motility.
WYAMYCIN S (tetracycline) inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
250-500 mg orally every 6 hours for mild to moderate infections; up to 4 g/day for severe infections.
WYAMYCIN S (clarithromycin/sulfamethoxazole) is a fixed-dose combination. Adult: 1 tablet (500 mg clarithromycin/800 mg sulfamethoxazole) orally every 12 hours for 7-14 days.
None Documented
None Documented
1.5-2 hours in adults; prolonged to 5-6 hours in severe hepatic impairment. In anuria, half-life not significantly affected.
2-3 hours in normal renal function; prolonged to 24-48 hours in end-stage renal disease.
Primarily biliary-fecal (90-95% as unchanged drug and metabolites); renal excretion accounts for 2-15%.
Renal (90-95% unchanged via glomerular filtration) and biliary (<5%).
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic